The CIS-treated group showed a significant decrease in SOD (p ≤ 0.05) and GSH (p ≤ 0.001) gene expression, respectively, and showed a significant (p ≤ 0.0001) increase in CytP450 gene expression as compared to the EQ-treated group. Here, SOD1 is linked to in situ carcinoma.